**Pneumocystis jiroveci Pneumonia**

Abida K. Haque and Patrick A. Adegbeyoga

Pneumocystis pneumonia (PCP) is one of the most common pulmonary infections in persons with impaired cell-mediated immunity, and particularly those infected with human immunodeficiency virus (HIV).\(^1\)-\(^7\) Pneumocystis was first described in the lungs of guinea pigs, during experiments on American trypanosomiasis by Carlos Chagas\(^8\) in 1909 and by Antonio Carinii\(^9\) in 1910. Both considered the cysts of pneumocystis as part of the trypanosome’s life cycle. Shortly afterward the Delanos\(^10\) found identical forms in the lungs of rats that had not been infected with trypanosomes and recognized the organism as a separate species. The name *Pneumocystis carinii*, was given to this organism as a generic name (Greek: *pneumon*, “lung”; *kystis*, “cyst”), honoring Carinii.\(^11\)

The organism attained medical significance, when van der Meer and Brug\(^12\) in 1942, and later Vanek, Jirovec, and Luke suggested it to be the cause of interstitial plasma cell pneumonia, a disease affecting premature and debilitated infants in central and eastern Europe.\(^12\),\(^13\) In the 1960s *P. carinii* was recognized as an important cause of pneumonia in immunocompromised adults on corticosteroids and cancer chemotherapy, in organ transplant recipients, and in children with primary immunodeficiency syndromes.\(^4\) The emergence of acquired immune deficiency syndrome (AIDS) in the 1980s thrust *P. carinii* to the forefront once again, as a leading cause of morbidity and mortality in immunocompromised individuals.\(^14\) Pneumocystis organisms infecting human beings have recently been named *P. jiroveci*.\(^15\)

The complete identification and classification of pneumocystis has taken many decades. Although initially considered to be a protozoan, it is now generally agreed that pneumocystis is a fungus. The ribosomal RNA is homologous to that found in fungi.\(^16\),\(^17\) A study of the small subunits of ribosomal RNA (16S-like rRNA) of *P. carinii* and the fungus *Saccharomyces cerevisiae* shows close evolutionary linkage between the two.\(^16\) The pneumocystis organisms also stain with methenamine silver stains, further supporting a closer link to fungi rather than protozoa. Recent molecular genetic studies that demonstrate the thymidylate synthase and dihydrofolate reductase genes to be similar to their counterparts in *S. cerevisiae* support the classification of pneumocystis as a fungus.\(^17\) Furthermore, ultrastructural studies have failed to show the cytoskeletal elements and complex organelle systems characteristic of protozoa.\(^18\),\(^19\)

Pneumocystis organisms are ubiquitous and globally distributed, having been identified in virtually every mammalian species including humans as well as rabbits, dogs, goats, cats, swine, chimpanzees, owl monkeys, and horses.\(^20\)-\(^26\) The organisms have a wide range of genetic characteristics that are host specific.\(^27\) The pneumocystis that infects humans, *P. jiroveci*, is different from the one that infects rats, and there is no cross-species infection.\(^15\),\(^27\) This observation was confirmed when polymerase chain reaction (PCR) applied to the human pneumocystis identified only *P. jiroveci*.\(^28\),\(^29\)

**Epidemiology**

The epidemiologic features of *P. jiroveci* are poorly understood. Experimental studies have shown that the infection is acquired by inhalation.\(^30\)-\(^33\) There does not appear to be a natural transmission of *P. jiroveci* across species.\(^27\),\(^34\)-\(^36\) Immunosuppressed rats and nude mice acquire the infection by direct and distant contact with infected animals. In humans, the major predisposing factor is impaired cellular immunity as seen in AIDS, protein-calorie malnutrition, primary immunodeficiency diseases, immunosuppressive therapy with corticosteroids or other agents, and prematurity.\(^37\) The organisms are present in practically every part of the world, including the temperate, tropical, and polar regions.\(^38\) The use of molecular technology through the dihydropteroate synthase (DHPS) locus analysis has facilitated epidemiologic study of the prevalence of *P. jiroveci* in the human population. Identical genotypes of *P. jiroveci* were found in
the two groups of immunocompetent infants and adults with pneumocystis infection in a study from France, suggesting that the transmission cycles of infection in all individuals parasitized by P. jiroveci are linked with a common human reservoir.\textsuperscript{39,40}

It is not clear whether there is an environmental reservoir for P. jiroveci, although mammalian lung appears to be a natural home.\textsuperscript{35} The isolation of pneumocystis DNA from rural outdoor locations and a seasonal variation in infection in patients suggest that there may be an environmental reservoir.\textsuperscript{41} Primary exposure to pneumocystis occurs early in life, so that most children have serum antibody by the age of 2 to 3 years.\textsuperscript{52-54} This is presumed to be an asymptomatic infection. The organisms remain latent within the host, and propagate when the host immune system becomes compromised. Several studies using PCR have found no evidence of pneumocystis DNA in the lungs of immunocompetent individuals, and do not support the latent reactivation theory.\textsuperscript{41,46-48} There are also experimental data in rat models that suggest that pneumocystis organisms do not persist in the lungs of immunocompetent individuals.\textsuperscript{49} Transmission of pneumocystis has been shown to occur animal to animal when they had a common air supply, in immunosuppressed as well as immunocompetent models, although the latter had a subclinical transient infection.\textsuperscript{41,50,51} Clinical studies have suggested the occurrence of human to human transmission of pneumocystis organisms.\textsuperscript{52-56}

Acquired immune deficiency syndrome patients have been found to develop immunoglobulin M (IgM) antibodies with recurrent episodes of pneumocystis pneumonia.\textsuperscript{57} It has also been shown by immunoblotting that P. jiroveci (carinii) antigen recognition patterns in bronchoalveolar lavage (BAL) fluid can change with recurrent episodes of pneumonia.\textsuperscript{58} These findings may represent infections with different antigenic strains or antigenic changes in the existing strain of P. jiroveci. Recently, mutations in the DHPS gene of P. jiroveci were identified and used in epidemiologic studies of P. jiroveci. In one study of 139 HIV-infected patients with pneumocystis infection, 19% of patients with prior sulfa treatment had the gene mutation, compared to 4% of those without treatment.\textsuperscript{59} Co-infection with multiple strains of P. jiroveci was found in 20% to 30% of cases, suggesting that recurrent infections may be related to reinfection with a new strain rather than reactivation.\textsuperscript{60} The DHPS gene–type variation was related to the place of diagnosis and not the place of birth, suggesting the infection to be recently acquired. Additionally, 54% of P. jiroveci strains in newly diagnosed HIV-infected patients demonstrate DHPS gene mutations. Since these patients were not treated with sulfa drugs, such mutations suggest that the infection was acquired from patients who had received prophylactic sulfa. The authors therefore believed that these findings represent evidence for person-to-person transmission of pneumocystis. Person-to-person spread of P. jiroveci is also suggested by outbreaks of infection in malnourished infants in orphanages and in hospitals caring for immunosuppressed patients.\textsuperscript{37}

Life Cycle

The major obstacle to study the life cycle and biology of pneumocystis is the inability to sustain propagation of the organism outside the lung.\textsuperscript{28} Our understanding of the life cycle of P. jiroveci derives mainly from detailed ultrastructural studies.\textsuperscript{61-65} Four developmental forms are described: trophozoites, cysts, precysts, and sporozoites (also known as intracystic bodies).\textsuperscript{66,67} All investigators have consistently identified the trophic (trophozoite) and the cyst stage, and also an intermediate precyst stage. Experiments using P. carinii from lungs of infected rats and human lung cell cultures have been partially successful in growing the organisms to study the life cycle.\textsuperscript{68} Based on the cell culture studies, it was proposed that several developmental pathways may exist.\textsuperscript{68} The environment may play a significant role in determining the predominant method of replication as it does in many yeast or other microorganisms.\textsuperscript{69,70} In tissue culture, at least two methods of development were proposed: an asexual cycle and a sexual cycle. Figure 13.1 shows the two cycles of P. jiroveci pneumonia development. The asexual cycle involves mitotic replication of the trophic forms. The sexual cycle involves the continued development of precyst stages to mature cyst forms, and the development of elongated daughter forms within the cyst, followed by excystation and collapse of the cyst.

The vegetative forms of pneumocystis, the trophozoites, are 2 to 8\textmu m in diameter, and attach to type I alveolar epithelial cells. Although initially haploid, the trophozoites are believed to attain a diploid chromosomal number by gametic fusion.\textsuperscript{37} The trophozoites enlarge and develop into diploid precysts through a process of cell wall thickening.\textsuperscript{35} Sporozoites then develop within the precysts following meiosis and mitosis, a process referred to as asporogony.\textsuperscript{67,69} Mature cysts contain eight haploid sporozoites that become trophozoites, following rupture of the cyst wall, and recapitulate the life cycle.

The cyst is the largest and most easily recognized developmental stage of P. jiroveci. As demonstrated with Gomori’s methenamine silver (GMS) stain, the cysts are thick-walled spherules, 5 to 7\textmu m in diameter, that assume a cup or crescent shape when collapsed. The cyst wall is trilaminar, 70 to 160nm in thickness, and shows a thick electron-dense outer layer, an electron-lucent middle layer, and a thin inner cell membrane.\textsuperscript{37} The cyst wall stains well with methenamine silver stain, cresyl echt
Pneumocystis jiroveci Pneumonia

Figure 13.1. Diagrammatic representation of the developmental cycles of P. carinii, in vitro. The asexual cycle: A1, trophic form; B1, mitotic replication of trophic form; C1, trophic forms, products of binary fission. The sexual cycle: A, B, isogametic forms; C, karyogamy; D, early precyst, diploid zygote; E, intermediate precyst, beginning of mitotic replication of nuclei; F, intermediate precyst, four nuclei; G, intermediate precyst, completion of nuclear replication, eight nuclei; H, late precyst, migration of nuclei to periphery; I, late precyst, initiation of compartmentalization of daughter forms; J, early cyst, completed separation of daughter forms; K, mature cyst, eight rounded daughter forms within a thick wall; L, cyst containing ellipsoidal daughter forms; M, cyst containing elongated daughter forms; N, cyst containing thin, very elongated daughter forms; O, collapsed, excysted cyst with trophic form. The progressive elongation of the daughter forms within the cyst stages L to N may represent the process required for excystation. These forms have been seen repeatedly in culture and in infected rat lung homogenates, although the actual process of excystment was not observed. (From Cushion et al. Copyright 1988, with permission from Macmillan Publishers Ltd)

It has been shown that the silver particles are deposited only on the electron-lucent middle layer of the cell wall; this explains the lack of staining of the trophozoites, which lack this layer. Many studies have examined the composition of the cell wall. The cyst wall is rich in carbohydrates, lectins, β-1,3-glucan, and lipids, including sphingolipid fatty acids and cholesterol. Treatment of P. carinii cysts with zymolyase, a β-1,3-glucanase, disrupts the cyst wall and liberates the surface antigens. Ergosterol has not been detected in many studies, which explains the resistance of P. jiroveci to sterol synthesis inhibitors, such as amphotericin B and ketoconazole.

Most cysts contain up to eight spherical daughter forms or intracystic bodies, also known as sporozoites that are 1 to 2 μm in diameter and surrounded by a double unit membrane. The sporozoites have a single nucleus, a mitochondrion, abundant endoplasmic reticulum, ribosomes, as well as microtubules and vacuoles. They are reported to be attached to each other and to the cyst wall by a thread or stalk-like structure. Many cysts contain single or paired, comma-shaped structures that are localized areas of thickening of the inner layer of the cyst wall. These distinctive argyrophilic structures help to distinguish the cysts of P. jiroveci from nonbudding fungi and other pathogens. Although seen best with GMS, the thickened foci can also be stained with toluidine blue O, but not reliably with the Gram-Weigert stain. None of the cyst wall stains demonstrate the sporozoites or trophozoites, although the membranes of the latter may stain faintly in specimens heavily overstained with GMS.

The sporozoites and trophozoites can be visualized with the appropriate special stains in smears and imprints, mainly because of their nuclear staining. The sporozoites are seen as clusters of small nuclei surrounded by an unstained cyst wall, whereas the trophozoites appear as a meshwork of honeycombed spaces, many of which contain a dot-like nucleus.

The trophozoites may be difficult to distinguish from background fibrin or tissue elements. In lung sections they appear ameboid, with broad pseudopodia and polar aggregates of tubular cytomembranous processes, termed “filopodia.” The filopodia increase the surface area of the trophozoites and may help in nutrition and transport of enzymes to the environment; they are not organelles of attachment. In unfixed preparations the trophozoites appear as oval bodies resembling a cluster of grapes. The trophozoites have a cell wall with three layers similar to the cyst; however, the middle electron-lucent layer is thin and poorly developed. Each trophozoite contains a single nucleus, cytoplasmic organelles, and glycogen, although not all of these elements are seen in every trophozoite. Electron micrographs of the trophozoites demonstrate the filopodia and the relationship between the filopodia and the pneumocytes (Figs. 13.2 and 13.3). Occasionally, trophozoites assume shapes that suggest reproduction by either binary fission or endodyeny. The trophozoites tend to cluster in large aggregates, where
Figure 13.2. Electron micrograph of alveolar exudates in AIDS patient with pneumocystis pneumonia. Cyst containing six merozoites is seen between arrows. Next to the cyst is a matur­
ing trophozoite (T) without filopodia. Two collapsed cysts (C) are also present. Note that the upper cyst has discrete areas of capsular thickening corresponding to the darkly staining bodies seen with Gomori’s methenamine silver stain. Uranyl acetate, lead citrate. (Courtesy of Dr. Richard Sobonya, University of Arizona.)

they mold against each other in sheet-like pieces of a jigsaw puzzle. Each large cluster of trophozoites contains only a few admixed cysts. It is the clustering of the trophozoites that produces the appearance of alveolar “honeycomb exudate” seen on light microscopy. The intermediate stage between the trophozoite and the cyst forms the precyst stage, which demonstrates considerable morphologic variability. The precysts are oval in shape and 4 to 6 μm in diameter. The cell wall is up to 100 nm in thickness, with an electron-lucent layer that is thicker than that of trophozoites. The cytoplasm contains one or more nuclei, mitochondria, free ribosomes, microtubules, vacuoles, and glycogen granules. Ultrastructural studies have identified three subtypes of the precyst stage, characterized by progressive thickening of the cell wall and an increasing number of nuclei from one nucleus in the early precyst to four or more in the late precyst. 38,66,77,78

The developmental forms of *P. jiroveci* are not seen clearly in routine histologic sections. A variety of special stains may be used to make the diagnosis. These stains are grouped into two categories: those that stain the cyst wall, and those that stain the nuclei of the trophozoites and sporozoites. 79 The latter group, which can be applied only to imprint smears and cytology specimens, includes a variety of Romanowsky stains (Giemsa, Wright, Diff-Quik), polychrome methylene blue, and Gram’s stain. The cyst wall stains can be applied to tissue sections as well, and are preferred for routine diagnostic work. These stains include Gomori’s (Grocott) methenamine silver (GMS) and its rapid variants, toluidine blue O, and Gram-Weigert methods; GMS is preferred by most pathologists. 80

Stains for sporozoites/trophozoites have been advocated for diagnosis because of their simplicity and rapidity. However, a well-prepared GMS stain is by far the most reliable and sensitive nonimmunologic stain for the diagnosis of *P. jiroveci*. Recently described rapid GMS variants have shortened the time required for specimen staining. 80–84 A microwave method, described originally by Brinn, 81 can provide high-contrast slides of optimal

Figure 13.3. A. Electron micrograph of several trophozoites (T) attached to type I pneumocyte epithelium of the alveolar wall (I). MAC, macrophage; INT, alveolar interstitium; CAP, alveolar capillary. Uranyl acetate, lead citrate. B. Details of electron micrograph in A, taken from the area to left of CAP. Filopodia (arrows) are apparent especially in conjunction with type I pneumocyte epithelium. Uranyl acetate, lead citrate. (Courtesy of Dr. Richard Sobonya.)
quality in about 20 minutes and can be applied to any standard specimen. Combined methods that demonstrate both cyst walls and the nuclei of sporozoites and trophozoites, although aesthetically pleasing, offer no advantage over a good methenamine-silver stain.

**Molecular Biology**

Molecular studies of rat-derived *P. carinii* show the genome to be between $7 \times 10^6$ and $1 \times 10^7$ based on summation of *P. carinii* chromosomes in pulse-field gel electrophoresis. This genetic material is arranged as 13 to 19 chromosomes and is between 295 and 710 kilobase (kb) in size. The karyotype of human-derived *P. jiroveci* appears different from that of rat-derived organisms, but has not been well characterized. Three genes have been cloned from rat-derived *P. carinii*, including 18S RNA, dihydrofolate reductase, and thymidylate synthase gene. Since then, the *DHPS* gene and the internal transcribed spacer (ITS) region of *P. jiroveci* have been studied extensively in human pneumocystis infections. *DHPS* gene mutations are reported to be associated with sulfa/sulfone resistance in patients who had previously received prophylaxis. The prevalence of *DHPS* gene mutations was reported to be markedly increased in the United States since the use of prophylactic sulfa drugs. However, another study from Portugal reports no association between *DHPS* types or therapy and response to *Pneumocystis* therapy. This same study found a subtype of the ITS region of nuclear rRNA, type Ne, to be associated with treatment failure, childhood infection, and early death.

**Immunobiology of Pneumocystis**

Antigenic studies of pneumocystis using Western blot technique have revealed several major antigens. The most prominent surface antigen of pneumocystis is seen as a band of 116 kDa on polyacrylamide gel electrophoresis. There is cross-reactivity between this antigen from humans and other mammals. Another major class of antigens in rodent-derived *P. carinii* migrates in the 45- to 50-kDa range. The relationship of this antigen to the 116-kDa antigen is not clear. A third antigen that is the most prominent feature of human-derived pneumocystis is a broad intensely staining band between 35 and 45 kDa. This is the most common band found in the lungs and bronchoalveolar fluid of patients with *P. jiroveci* infection, while the 116-kDa band is less prominent in these specimens.

Exposure to pneumocystis organisms evokes an immune response in the host. Serologic studies using indirect immunofluorescence (IF) and enzyme-linked immunoabsorbent assay (ELISA) have demonstrated serum antibodies to *P. jiroveci* in childhood under conditions of natural exposure. These antibodies are primarily directed against the 35- to 45-kDa band antigen, although antibodies to other bands were also recognized. This study also found that >90% of AIDS patients developed IgM or IgG antibodies to the 35- to 45-kDa band and other antigens with recurrent episodes of pneumocystis infection. The role of these antibodies is unclear; however, there is some evidence that they may function as opsonins.

The development of PCP is related to impairment of cell-mediated immunity. The most prominent disease in this category is AIDS, although there has been an increase in non-AIDS patients also. In AIDS and HIV infection, there is a decline in the number and function of circulating CD4 T-helper cells, the increased incidence of PCP being directly proportional to the fall in CD4 T lymphocytes.

Pneumocystis organisms are host-specific, but the reason for this stringent specificity is not clear. *P. jiroveci*, the only pneumocystis identified in humans, has a unique tropism for the lung, where it exists primarily as an alveolar pathogen. A few cases of invasive infection with dissemination are reported with severe immunosuppression or overwhelming infection of the host. The availability of molecular techniques has identified key molecules in the cell cycle, signal transduction, and metabolic pathways of pneumocystis. The first specific molecule identified was glycoprotein A, a major surface glycoprotein with an integral role in the attachment of pneumocystis to host cells. This surface glycoprotein is immunogenic and antigenically distinct in each form of pneumocystis infecting various mammalian hosts. The major component of the cyst wall is β-1,3-glucan, and the pneumocystis β-1,3-glucan synthetase gene, *GSCI*, which mediates the polymerization of uridine 5'-diphosphoglucose into β-1,3-glucan. Inhibitors of β-1,3-glucan synthetase are effective in clearing the cyst forms of pneumocystis from lungs of infected mammals. The cyst wall also contains chitins and other complex polymers, including melanins that provide stability to the cell wall and invoke an inflammatory response in the lungs.

Several signal-transduction molecules have been recently identified in pneumocystis. These include *cdc2* cyclin-dependent kinase, *cdc13* B-type cyclin, *cdc25* mitotic phosphatase, and pneumocystis mitogen (PCM)-activated protein kinase. Furthermore, the finding of enhanced activity of PCM in the trophozoites as compared with the cyst forms suggests that the trophozoites may use this pathway for transitions in the life cycle. During infection, the trophozoites adhere tightly to the alveolar epithelium, activating specific signaling pathways in the organism, including the gene encoding PCSTE20.
kinase, which signals responses for mating and proliferation in fungal organisms. Other signaling molecules identified in pneumocystis include the pheromone receptors, heterotrimeric G-protein subunits, and transcription factors. Currently, some of these specific molecules are under intense research studies as potential drug targets. These include dihydrofolate reductase (target of trimethoprim), thymidylate synthase, inosine monophosphate dehydrogenase (target of mycophenolic acid), S-adenosyl-L-methionine:sterol C-24 methyl transferase (involved in biosynthesis of sterol), and lanosterol 14(α)-demethylase (the target enzyme of azole antifungal drugs).

**Pathogenesis of Infection**

Pneumocystis infection is acquired by inhalation. When the organism is deposited in the alveoli, the first critical step in the establishment of infection is attachment to the type I pneumocyte, through interdigitation of their cell membrane to the alveolar cell membrane. This binding is facilitated by the interaction of host proteins, fibronectin and vitronectin, which bind to the surface of the trophozoites and mediate the attachment to integrin receptors of the alveolar cells. The subsequent events depend on the immune status of the host; the organism can remain quiescent for a long period of time, and then proliferate when the host becomes immunocompromised. Other investigators suggest that the organisms remain in the lungs for only a short time. In an immunocompromised host, the organisms start to proliferate, and the alveoli become progressively filled with masses of the pneumocystis organisms. In animal models, *P. carinii* organisms increase from $<10^5$ to $10^6$ or $10^7$ in 8 to 10 weeks. It is presumed that *P. jiroveci* replicates in a similar manner in humans. The proliferation of *P. jiroveci* results in the accumulation of the typical foamy, honeycomb-like alveolar exudates. Although the type I alveolar cells appear vacuolated and eroded in infected tissues, there is no evident disruption of structure or barrier function in lung epithelial cell cultures. Ultrastructural studies have shown the alveolar exudate to contain abundant fibronectin, vitronectin, and increased surfactant proteins A and D. Surfactant protein B, in contrast, is reduced during pneumocystis infection. The reasons for the increased surfactant protein A (SP-A) levels are poorly understood; however, both surfactant proteins A and D interact with the surface glycoprotein A component of pneumocystis, and modulate its interaction with macrophages. Changes in the type I pneumocytes are followed by type II pneumocyte hyperplasia, suggesting a reparative response. Long-term survival of patients with pneumocystis infection is often associated with alveolar damage and interstitial alveolar fibrosis.

**Host Immune Responses**

Pneumocystis infection elicits both humoral and cellular immune responses in the host. Epidemiologic studies have shown that antibodies to the organism are acquired in early childhood. There is increasing evidence to support the role of humoral immunity in host defense against pneumocystis. Passive immunization with specific monoclonal antibody is shown to confer partial protection against *P. carinii* in animal models.

Pneumocystis infection invokes a cellular response with production of inflammatory cytokines and chemokines. These inflammatory responses are required to control the infection, but an exuberant inflammatory response may result in pulmonary injury. Complex interactions between the inflammatory cells and the soluble mediators produced by these cells facilitate the clearing of infection, but may result also in lung injury. The key inflammatory cells include CD4+ T lymphocytes, alveolar macrophages, and neutrophils. The complex interaction among the inflammatory cells, the soluble mediators, and the immune responses is presented in Figure 13.4.

**Lymphocytes**

The activity of CD4+ T lymphocytes is pivotal in host defense against pneumocystis, in both humans and animals. A reduction in CD4+ T-lymphocyte count to less than 200/mm³ increases the risk of pneumocystis infection. CD4+ T cells proliferate in response to the
pneumocystis antigens and generate cytokine mediators, including lymphotactin and interferon-γ. Lymphotactin is a chemokine that serves as a potent chemoattractant for lymphocyte recruitment. Interferon-γ activates macrophages to produce tumor necrosis factor-α (TNF-α), superoxides, and reactive nitrogen radicals. Aerosolized interferon-γ has been shown to reduce pneumocystis infection in rats, regardless of CD4+ cell depletion. Macrophage-derived TNF-α and interleukin-1 (IL-1) are necessary for initiating pulmonary responses that are mediated by CD4+ T cells. An undesirable effect of T-lymphocyte activation, however, is pulmonary injury and functional impairment. Pneumocystis infection also results in a marked accumulation of CD8+ T lymphocytes in the lung.

Macrophages

Alveolar macrophages are the principal cells mediating the uptake and degradation of pneumocystis in the lung, mediated either through the opsonins in the epithelial-lining fluid, or through the macrophage mannose receptors that interact with the surface mannoprotein, glycoprotein A, of the pneumocystis. Once phagocytosed, the organisms are incorporated into phagolysosomes and degraded. In response to the phagocytosed pneumocystis organisms, a variety of inflammatory cytokines, chemokines, and eicosanoid metabolites are produced. These mediators, however, in addition to eradicating pneumocystis, also produce lung injury. The macrophage function is impaired in patients with AIDS and malignancies, resulting in impaired clearance of pneumocystis.

Cytokines and Chemokines

The production of TNF-α by alveolar macrophages is mediated by recognition of the β-glucan component of the pneumocystis cell wall. Macrophages possess several potential receptors for glucans, including CD11b/CD18 integrin (CR3), dectin-1, and toll-like receptor 2. The activation of macrophages is facilitated by host vitronectin and fibronectin that bind glucan components on pneumocystis cell wall. Tumor necrosis factor-α plays a significant role in the clearance of pneumocystis. It promotes the recruitment of neutrophils, lymphocytes, and monocytes, and induces the production of other cytokines and chemokines, including IL-8 and interferon-γ, which stimulate further recruitment and activation of inflammatory cells.

Chemokines such as IL-8, macrophage-inflammatory protein-2, and the interferon-inducible protein of 10kDa are chemoattractants for neutrophils and important inflammatory mediators during pneumocystis infection. Interleukin-8 production is correlated with neutrophil infiltration with release of reactive oxygen radicals, proteases, and cationic proteins, resulting in capillary endothelial and alveolar epithelial cell injury, in turn resulting in impaired gas exchange. Increased levels of IL-8 in BAL fluid are correlated with poor prognosis.

Clinical Features of Pneumocystis Pneumonia

There are two major clinical forms of P. jiroveci pneumonia, each with a different epidemiologic pattern: (1) the infantile form, designated plasma cell interstitial pneumonia; and (2) the adult form, or pneumonia in immunocompromised host. Plasma cell interstitial pneumonia, also called the “epidemic form,” historically occurred in institutional settings in underdeveloped countries, mainly affecting premature, malnourished children. The infection is characterized clinically by progressive respiratory distress in infants, and histologically by a prominent pulmonary interstitial plasma cell infiltrate. This disease has practically disappeared from the Western world, but is still found in developing countries. Clinically, the infants gradually develop respiratory difficulty characterized by tachypnea, cyanosis, cough, and progressive respiratory failure. The chest roentgenogram shows diffuse pulmonary infiltrates and focal or diffuse consolidation.

The adult infection, also called the “sporadic form,” is one of the leading causes of fatal opportunistic infection in AIDS patients and other immunocompromised hosts. This infection is more frequent in the United States and other developed countries, and indicates an underlying cellular immune deficiency with impairment of CD4+ (T-helper) lymphocyte function. Diseases that predispose to pneumocystis pneumonia include congenital immunodeficiency diseases, immunodeficiency induced by cytotoxic agents and corticosteroids, and other acquired immunodeficiency. Before the AIDS epidemic, most adult patients with pneumocystis either had acute leukemia or were leukopenic from chemotherapy. Now these patients are vastly outnumbered by AIDS-associated pneumocystis. The incidence of PCP has undergone a significant reduction with the institution of chemoprophylaxis. At the beginning of the AIDS epidemic, PCP represented the most common AIDS index diagnosis, and the most life-threatening opportunistic infection, with an incidence of 44% to 74%. Approximately 80% of AIDS patients developed PCP during the course of their disease. The incidence of PCP in HIV-seropositive patients started to decrease in 1987, with only 16% of new index AIDS cases reported in 1993, almost exclusively due to the institution of chemoprophylaxis and antiretroviral therapy. In those individuals
not receiving chemoprophylaxis, it still represents a serious pulmonary infection. 

The clinical and radiographic findings in sporadic P. jiroveci infection are not specific, and mimic those of other opportunistic infections. In AIDS patients, the onset of symptoms is more insidious. The fall in the circulating CD4 T cell count usually correlates with the development of the pneumonia, with the vast majority of infections occurring when the CD4 lymphocyte count is <200 cells. The typical clinical presentation in HIV-seropositive patients is an insidious onset, including fever, dyspnea, tachypnea, and nonproductive cough. Less frequently, weight loss, chest pain, night sweats, chills, fatigue, and malaise have been reported. This is in contrast to the more acute presentation of HIV-seronegative immunocompromised patients. Physical findings are often mild compared to the degree of symptomatic respiratory impairment. There is, however, a subset of HIV-seropositive patients that present with an acute, fulminant onset, progressing to respiratory failure within 1 to 2 weeks. The disease in non-AIDS patients may vary from an acute illness with an abrupt onset to a more indolent disease. Symptoms often start after corticosteroids are tapered or discontinued, and are present for a short time, 1 to 2 weeks before a diagnosis of pneumocystis pneumonia is established.

In general, patients with AIDS-associated PCP have significantly more pneumocystis organisms in their lungs, with fewer neutrophils, than those patients without AIDS. The smaller number of inflammatory cells in AIDS-related pneumocystosis correlates with better oxygenation and survival compared with non-AIDS-related infection. The mortality rate in patients with AIDS is 10% to 20% during the initial infection, but the rate increases substantially with the need for mechanical ventilation. Patients with non-AIDS-related pneumocystosis present with an abrupt onset of respiratory insufficiency that may correlate with a tapering or increased dose of immunosuppressive therapy. These patients have more neutrophils and fewer pneumocystis organisms in the lungs than do patients with AIDS-associated pneumocystis pneumonia. The mortality rate in patients with non-AIDS-related pneumocystis pneumonia is 30% to 60%, with a greater risk of death among patients with cancer than among patients with transplants or other diseases such as connective tissue disorders.

Extrapulmonary Infection

Extrapulmonary infection is being recognized with increasing frequency, and appears to correlate with the use of inhaled prophylactic pentamidine therapy. A review of autopsy cases with AIDS shows an incidence of extrapulmonary pneumocystosis of 2.5% to 2.8% between 1980 and 1994. Concomitant pneumocystis pneumonia was present in 45% of patients. The most frequent spread of infection is to the hilar lymph node, followed by bone marrow, liver, spleen, and adrenal glands, followed by gastrointestinal tract, thyroid, genitourinary tract, heart, pancreas, eyes, and ears. Less frequently, skin, cerebral cortex, pituitary gland, and parathyroid glands are involved. Most patients who have disseminated extrapulmonary pneumocystosis have no specific symptoms. Some patients, however, may experience local pain or a mass; rarely, there is clinical and laboratory evidence of organ (e.g., renal, otic, or bone marrow) failure. A case of digital vasospasm and necrosis secondary to microemboli containing pneumocystis organisms has been reported. P. jiroveci probably spreads from the lungs by hematogenous or lymphatic routes to these sites.

Clinical manifestations of extrapulmonary pneumocystosis are variable, and may range from asymptomatic infection to end-organ failure. Computed tomograms may show low-attenuation lesions that progressively calcify in a rim-like or punctuate manner. Although chemoprophylaxis is considered a risk factor in extrapulmonary infection, only 50% of the patients had received the therapy in one series. The detection, using PCR amplification, of P. jiroveci (carinii) DNA in the blood of patients with PCP provides supporting information in cases with extrapulmonary infection. Pathologic findings in the extrapulmonary sites consist of the typical eosinophilic foamy material with a variable inflammatory infiltrate. The organisms can be demonstrated with the usual silver stains or immunoperoxidase stain.

Radiographic Features

Typical radiographic findings in PCP include bilateral diffuse interstitial and alveolar infiltrates, initially predominating in parahilar regions and lower lung fields, which may progress to extensive areas of air-space consolidation involving much of both lungs. The radiographic picture presents a combination of air-space consolidation with variable interstitial infiltrate. Atypical manifestations include unilateral and upper lobe infiltrates, nodular lesions, lobar consolidation, cavitation within a mass, localized nodule or consolidation, pneumatocele, pneumothorax, pneumomediastinum, subsegmental atelectasis, bronchectasis, hilar and mediastinal lymphadenopathy, and pleural effusion. Classic, ground-glass perihilar interstitial infiltrates are seen in the early stages, which progress to involve all lung fields in untreated patients. The infiltrates may develop a coarse pattern with homogeneous consolidation and air bronchograms. The lung apices are relatively spared, but the use of prophylactic inhaled pentamidine has resulted in involvement of
the apices, presumably due to the relatively poor distribution of aerosol pentamidine to these regions. The radiographic features of PCP in those with and without HIV infection and with and without chemoprophylaxis are summarized elsewhere. As many as 10% to 20% of AIDS patients with PCP present initially with no detectable radiographic abnormalities. In these cases, high-resolution computed tomography may reveal extensive ground-glass attenuation or cystic lesions.

Immune Reconstitution Syndrome

Recently, the phenomenon of immune reconstitution syndrome was described in a small group of patients who developed a pneumonic illness after treatment for pneumocystis pneumonia and subsequent highly active antiretroviral therapy (HAART) initiation. During the second illness, none of these patients had an identifiable pathogen on bronchoscopy. The mean BAL CD4/CD8 ratio was 0.54, which was much higher than the ratio of 0.07 seen in a cohort of HIV-infected patients undergoing bronchoscopy for a variety of respiratory complaints. The authors suggested that this influx of CD4 cells might represent immune reconstitution. Another similar case was reported in which the BAL and tissue samples taken at the time of recurrent respiratory illness were negative on routine stains, but PCR confirmed the presence of pneumocystis. These reports suggest that subclinical infection with P. jiroveci can be present after clinical response to therapy and may trigger an inflammatory response upon reconstitution of the immune system.

Pathology of Pneumocystis jiroveci Pneumonia

The pathologic features of PCP have been described in patients with the epidemic or infantile infection, and more recently in the sporadic or adult infection.

Epidemic Pneumocystis Pneumonia (Infantile PCP)

Interstitial plasma cell pneumonia, also known as the epidemic or infantile form of non–AIDS-related PCP, is rarely encountered in the United States. It has an intense plasmacytic and lymphocytic interstitial inflammation. This morphologically nonspecific interstitial pneumonia resembles pneumonia associated with other opportunistic (especially viral) infections that are also prone to occur in premature, debilitated, or malnourished infants. Often, the correct diagnosis is suggested by the “honeycomb exudate” in alveolar spaces, but definitive diagnosis requires demonstration of the pathogen with an appropriate special stain or immunohistochemical reagent (see Fig. 7.42 in Chapter 7).

Sporadic Pneumocystis Pneumonia (Adult PCP)

Pathologic features of the sporadic P. jiroveci pneumonia, almost exclusively seen in immunocompromised adults, can be categorized in two major histopathologic groups: typical and atypical (Table 13.1).

**Typical Pathologic Features**

The typical or classical features are seen in the lungs of patients who are not on prophylactic treatment (HAART). Grossly, the lungs are heavy with a pale gray or tan, granular, firm, consolidated cut surface as seen in Figure 13.5. Nodules and cavities are occasionally encountered. Microscopically, a variety of patterns have been described in patients with and without AIDS.

The typical histopathologic pattern in AIDS-associated PCP is characterized by a mild interstitial chronic inflammation and type II pneumocyte hyperplasia, associated with eosinophilic, foamy intraalveolar exudates that expand the alveolar spaces (Fig. 13.6). At higher magnification, the exudate is punctuated with round basophilic dots that correspond to the nuclei of the sporozoites and trophozoites, and are best seen in tissue preserved with a good nuclear fixative, such as B5 solution. Recognition of the basophilic nuclear “dots” is helpful in the differential diagnosis of pneumocystis from alveolar edema and alveolar proteinosis, both with eosinophilic alveolar exudates, without any demonstrable nuclei. The alveolar exudate is composed predominantly of abundant P. jiroveci trophozoites admixed with cysts, membranotubular

| Table 13.1. Histologic patterns of Pneumocystis infection |
|----------------------------------------------------------|
| **Classical (typical) pattern**                           |
| Plasma cell interstitial pneumonia (epidemic PCP)        |
| Mild interstitial chronic inflammation, type II pneumocyte |
| hyperplasia (sporadic PCP)                               |
| **Atypical patterns**                                    |
| Diffuse alveolar damage                                  |
| Diffuse interstitial fibrosis                            |
| Necrotizing PCD                                          |
| Vasculitis                                               |
| Calcification                                            |
| Thin-walled cavities                                     |
| Granulomatous PCD                                        |
| Nonnecrotizing, poorly formed                            |
| Necrotizing                                              |
| Fibrocaseous nodules (solitary or multiple)              |
| Miliary granulomas                                       |

PCP, Pneumocystis pneumonia.
FIGURE 13.5. Gross photograph of lung from a patient who died within 5 days of onset of respiratory failure. The lung weighed 1750 g and showed a tan solid cut surface, consistent with diffuse alveolar damage (DAD).

hyaline membranes, and reactive epithelial cell proliferation may be seen. Because *P. jiroveci* cannot be cultivated on cell-free media in the clinical laboratory, the diagnosis of PCP depends on demonstration of the organisms in biopsy or cytology specimens.

**Atypical Pathologic Features**

Several studies have suggested that the histologic spectrum of pneumocystis pneumonia is much broader than the typical pattern described above. The first study that documented a broad spectrum of patterns was conducted before the onset of the AIDS epidemic; only about one third of the lung biopsy specimens showed the typical pattern of PCP. Notably, the foamy alveolar material was not found in approximately 50% of the specimens. Atypical findings included dense interstitial lymphocytic infiltrates, interstitial fibrosis, epithelioid granulomas, multinucleated giant cells, and focal calcifications (Table 13.1). This spectrum of changes in PCP has been confirmed in subsequent studies.

In a study from the National Institutes of Health (NIH), the atypical manifestations reported were interstitial chronic inflammation (57%), fibrosis (50%), numerous alveolar macrophages with desquamative interstitial pneumonia-like pattern (9%), granulomatous inflammation (5%), hyaline membranes (4%), interstitial pneumonitis (3%), cystic or cavitary lesions (2%), microcalcifications (2%), and vascular infiltration and vasculitis (1%). In 19% of the patients, alveolar exudates were absent, and in 2% there was a minimal histologic reaction.

**Interstitial Chronic Inflammation**

The presence of interstitial inflammation is the most common finding in PCP. The lymphocytic and plasma cell infiltrates within the alveolar septa are associated with mild expansion of the septa with type II pneumocyte hyperplasia. In one large series of biopsies of HIV-positive patients, an interstitial infiltrate was graded only as mild or moderate in nearly 90% of the patients. Figure 13.8 shows the classical features of interstitial chronic inflammation. If severe, the chronic infiltrate may be misinterpreted as lymphocytic interstitial pneumonia (LIP) or nonspecific interstitial pneumonia (NSIP), particularly if the typical foamy exudate is minimal. Intraalveolar cellular infiltrates are not a usual feature of active PCP, and when present, consist of macrophages that may contain intracytoplasmic pneumocystis cysts by silver stains. The presence of numerous intraalveolar macrophages may simulate desquamative interstitial pneumonia (DIP). Cysts have been described in the alveolar pneumocyte cytoplasm in the early phase of PCP.
13. Pneumocystis jiroveci Pneumonia

**FIGURE 13.6.** A. Low-magnification photomicrograph shows thickened alveolar septa with mild interstitial inflammation and fibrosis, lined by hyperplastic type II pneumocytes. The alveoli are filled with the typical foamy, eosinophilic exudate of *Pneumocystis*. B. Higher magnification shows an alveolus with the foamy/bubbly eosinophilic exudates and a few mononuclear cells. Basophilic dots are visible within the exudate. The alveolar septa have a few inflammatory cells and collagen, and are lined by hyperplastic type II pneumocytes. C. Immunostain demonstrates the cyst forms of *Pneumocystis* organisms, surrounded by inflammatory cells. The trophozoites also stain with the immunostain; however, these are not as clearly visualized as the cyst forms.

**FIGURE 13.7.** Gomori’s methenamine silver (GMS) stain shows the typical round and collapsed crescent or boat-shaped cyst forms of *Pneumocystis*.

**TABLE 13.2. Staining features of Pneumocystis**

| Stain                        | Structure identified | Tissue section  | Fluid smears/ imprints |
|------------------------------|----------------------|-----------------|------------------------|
| **Histochemical**            |                      |                 |                        |
| Gomori’s methenamine silver (GMS) | Cyst                 | +               | +                      |
| Rapid GMS                    | Cyst                 | Frozen section  | +                      |
| Romanowsky stains            |                      |                 |                        |
| Wright                       | Trophozoites         |                |                        |
| Giemsa                       | Sporozoites          |                |                        |
| Diff-Quik                    |                      |                |                        |
| Gram                         |                      |                |                        |
| Methylene blue               |                      |                |                        |
| **Chemofluorescence**        |                      |                 |                        |
| Papanicolaou stain           | Cyst                 | –               | +                      |
| Calcofluor white             | Cyst                 | +               | +                      |
| **Immunofluorescence**       |                      |                 |                        |
| Cyst                         | Trophozoites         | Frozen section  | +                      |
| Sporozoites                  |                      |                |                        |
| **Immunohistochemistry**     |                      |                 |                        |
| Cyst                         | Trophozoites         | +               | +                      |
| Sporozoites                  |                      |                |                        |
Interstitial Fibrosis

This pattern of *P. jiroveci* pneumonia may complicate long-standing, treated, or recurrent PCP. Interstitial fibrosis may be seen in >50% of patients with chronic PCP. This usually presents as a mild thickening and fibrosis of the alveolar septa, with deposition of loose, edematous fibrous tissue, and without architectural distortion of the lung parenchyma (Fig. 13.9A). In some cases, alveolar intraluminal fibrosis consistent with organizing pneumonia may be seen (Fig. 13.10). Many, if not most, of these cases are consistent with the organizing or proliferative phase of diffuse alveolar damage (DAD), which may also be the result of oxygen toxicity, concurrent viral infection, shock, or other recognized causes of DAD in HIV-positive patients, rather than injury by *P. jiroveci* (Fig. 13.9).

Diffuse Alveolar Damage

Diffuse alveolar damage may be seen both in AIDS patients and in other immunodeficient patients. Respiratory failure as a terminal event is one of the leading causes of death in AIDS patients. In a study of 196 autopsied AIDS patients, 34% died of acute respiratory distress syndrome (ARDS), expressed histologically as DAD. *P. jiroveci* was the most common organism, identified in 55% of these patients. Often, there is very little foamy material in the alveolar spaces, and the changes, therefore, may be misinterpreted as due to viral infection, oxygen toxicity, or a drug reaction unless an appropriate stain is used to demonstrate the cysts. The cysts may be quite sparse, and are usually found within the hyaline membranes lining the walls of alveolar ducts and alveoli (Fig. 13.11A–C). Figure 13.5 shows gross findings in the lung from a patient with DAD. Figure 13.11 demonstrates the features of DAD in the lung shown in Figure 13.5. The pneumocystis organisms are plastered along the alveolar walls within the hyaline membranes, and also present in the alveolar exudate (Fig. 13.11B). Dual immunostain for pneumocystis and alveolar pneumocytes (cytokeratin AE1/3) shows invasion of the alveolar interstitium and destruction of type II pneumocytes by the pneumocystis organisms (Fig. 13.8B). This finding may not be appreciated by the routine H&E or the usual single immunostain for pneumocystis.

Necrotizing PCP

Necrotizing PCP, seen mainly in patients with AIDS, is characterized by confluent parenchymal necrosis with lysis of alveolar septa. Grossly, parenchymal nodules and cavities ranging from 1 to 6 cm in diameter may be seen (Fig. 13.12). Histologically parenchyma is replaced by confluent eosinophilic foamy material in which there are abundant cysts of *P. jiroveci* (Fig. 13.13). Pneumocystis exudate infiltrates alveolar septa, a pattern referred to as “septal lysis,” resulting in lung necrosis and cavity formation (Fig. 13.13). Rarely, parenchymal necrosis is associated with pneumocystis vasculitis, characterized by massive infiltration of blood vessel walls by characteristic foamy material accompanied by mononuclear inflammatory cells and mural necrosis (Fig. 13.14). The histogenesis of the cavitary lesions is not clear; however, pulmonary infarction due to vascular invasion by pneumocystis trophozoites is considered a possible mechanism. Interestingly, about half of the patients with necrotizing pneumocystis pneumonia also have extrapulmonary pneumocystosis; vascular invasion is a possible mechanism of spread of infection.
Figure 13.9. A. Lung section from a patient with pulmonary fibrosis shows mildly fibrotic alveolar septa to the right of the thickened interlobular septum. There is diffuse fibrosis to the left of the septum. (Movat.) B. Another area of lung from the same patient shows alveoli filled with *Pneumocystis* exudate surrounded by fibrosis. Note dilated alveolar ducts with peripheral, ring-like fibrosis, consistent with fibrotic phase of DAD. (Movat.) C. Higher magnification of B shows the *Pneumocystis* exudate surrounded by hyperplastic type II pneumocytes. (Movat.)

Figure 13.10. Organizing pneumonia pattern. Lung section taken from a patient with an early stage of *Pneumocystis* infection shows mildly fibrotic alveolar septa. Two small alveolar ducts in the center of the field contain fibrous plugs.
FIGURE 13.11. A. Photomicrograph of lung seen in Figure 13.5 shows the typical histologic pattern of exudative stage of DAD. Alveolar ducts are dilated and lined by hyaline membranes, and surrounded by collapsed alveoli. Intraalveolar foamy exudates of pneumocystis are also visible. B. Higher magnification of the hyaline membranes show embedded pneumocystis cysts. (GMS.) C. Immunostain for pneumocystis may also be used to demonstrate the cysts and trophozoites in the hyaline membranes. D. Photomicrograph of lung from a patient with long-standing pneumocystis infection shows enlarged and atypical type II pneumocytes with high nuclear cytoplasmic ratio, as seen in atypical alveolar hyperplasia.

FIGURE 13.12. Necrotizing *Pneumocystis jiroveci* pneumonia. Apical subpleural cavity due to necrotizing PCP in a patient with AIDS.
Other lesions associated with necrotizing PCP include poorly formed granulomas (Fig. 13.15) and microcalcifications (Fig. 13.16), described in more detail below.

Cysts

Thin-walled, pneumatocele-like cysts may be seen in PCP, either in the parenchyma or in the subpleural areas (Fig. 13.17). Initially the walls of the cysts may be formed by alveoli filled with pneumocystis exudates in necrotizing PCP. Chronic or healed cavities have a thin fibrous wall with focal chronic inflammation (Fig. 13.17B,C). Focal microcalcifications may be present in the cyst wall. The large subpleural cysts presumably develop from either rupture or confluence of smaller parenchymal cavities. The cysts are usually empty, or contain a few macrophages and lymphocytes. Occasionally cysts may be colonized by organisms other than pneumocystis such as aspergillus or mycobacteria. Rupture of cavities leads to spontaneous pneumothorax.

Microcalcifications

Microcalcifications are an important atypical feature of PCP, and may be seen with or without the foamy exudates. Several patterns of calcification may be seen, including a “bubbly” pattern with vacuolations, a plate-like pattern, an elongated pattern, and a conchoidal pattern; these patterns were described in a study of 13 patients with microcalcifications. The authors postulate that the initial lesion is manifested by a form of long, thin calcifications that are always associated with active PCP. The “bubbly” plate-like calcifications are usually
associated with focal interstitial fibrosis and are a later phase of calcification. All calcifications contained *P. jiroveci* cysts on GMS stain, and thus represent dystrophic calcification of degenerated *P. jiroveci* organisms. The margins of cavitory lesions, as well as subpleural areas, may also develop microcalcifications. Figure 13.16 shows plate-like and conchoidal calcifications in the lung of a patient with AIDS.

**Vascular Permeation and Vasculitis**

Vascular permeation is not a common feature of PCP; however, when present, it may be a marker of extrapulmonary dissemination of *P. jiroveci*. The vascular wall shows an eccentric expansion of the intima by the characteristic eosinophilic foamy exudate, which may also infiltrate the muscular layer of the vessel wall. Chronic inflammation may be associated with the mural exudate (Fig. 13.14).

---

**Figure 13.16.** Necrotizing PCP with dystrophic calcifications.

**Figure 13.17.** Cystic lesions. **A.** Subpleural thin-walled cysts, the residual of healed cavitary PCP in a patient with AIDS. **B.** Intermediate stage of cyst development showing fibrous wall and necrotic exudate. **C.** Photomicrograph of cystic lesion shows no discernible lining. The cyst wall is composed of collapsed and fibrotic lung parenchyma.
13. Pneumocystis jiroveci Pneumonia

Granulomatous Pattern

Granulomatous inflammation in response to pneumocystis infection has been described both in AIDS patients and in immunodeficient patients without AIDS. In some patients, it has been associated with a nodular or cavitary pattern on chest radiograph.\textsuperscript{190,196,205,206} Frequently seen in necrotizing PCP, the granulomas are predominantly in alveolar spaces, and are usually loose and poorly formed, with or without necrosis (Fig. 13.15); see also Fig. 23.26 in Chapter 23).\textsuperscript{207-209} The granulomatous reaction surrounds, or is adjacent to, eosinophilic, foamy material composed of trophozoites and cysts of \emph{P. jiroveci}.

Rarely, well-formed granulomas with central necrosis may dominate the histologic picture in a manner reminiscent of miliary mycobacterial or fungal infection (Fig. 13.18).\textsuperscript{205,206,207} An even less frequent pattern of granulomatous PCP is that of a solitary nodule or a few discrete fibrocaceous lesions, similar radiographically and histologically, to tuberculomas or histoplasmosomas.\textsuperscript{210,211} Cyst forms may be sparse in the center of these well-formed necrotizing granulomas. An immunohistochemical stain for pneumocystis is helpful in locating sparse cyst forms and distinguishing them from histoplasma organisms (Fig. 13.18D).

Granulomatous PCP has been particularly associated with dissemination of pneumocystis to extrathoracic viscera.\textsuperscript{210,211} It is speculated that granulomatous PCP occurs in patients who are marginally, rather than severely, immunosuppressed.\textsuperscript{192,198} Because granulomatous reactions are infrequent in pneumocystis infection, every effort should be made to exclude other pathogens such as fungi and mycobacteria using special stains.
FIGURE 13.19. Photomicrograph shows *Pneumocystis* in the alveolar spaces and cytomegalovirus inclusions in the surrounding type II pneumocytes.

Hilar Lymphadenopathy

This is an infrequent manifestation of PCP. In some patients, lymphadenopathy is caused by underlying disease (e.g., lymphoma or leukemia) or reactive hyperplasia. In one patient, an intravenous drug abuser, enlarged lymph nodes contained typical foamy masses of *P. jiroveci* similar to those found in the alveolar spaces. This patient also had disseminated pneumocystosis.

Other Findings

A PCP infection in patients with AIDS is often associated with other infections, cytomegalovirus infection being one of the commonest. Figure 13.19 shows both infections in the same alveolus in a patient who died with AIDS.

Pathology of Treated Pneumocystosis

The effects of therapy on pathologic features of pneumocystis pneumonia were studied in patients who died of fulminant infection following therapy. Patients who died within the first week of therapy showed compact alveolar exudates that lacked the foamy appearance of typical infection, with fewer stainable organisms as compared to pretreatment biopsy. A second group of patients who died from 8 days to 8 weeks following therapy, had features of organizing DAD; however, all patients were treated with high concentration of oxygen. A third group of patients who responded to therapy and were considered to be cured of infection showed no residual pneumocystis organisms when autopsied 6 months to 2 years later. This study suggests that chronic interstitial lung disease does not develop as a result of pneumocystis infection in long-term survivors.

*P. jiroveci* can persist in the lungs of AIDS patients following therapy, even when there is a good clinical response. Pneumocystis cysts can persist in the lungs for up to 5 weeks or more following treatment with sulfa drugs. The viability of the trophozoites is not known, but if viable they may cause recurrent infection. Since cyst forms of *P. jiroveci* are known to persist for several weeks, the interpretation of repeat biopsy or cytology during this period should be cautious. There is also a case report that indicates preferential elimination of the cysts and persistence of trophozoites on treatment. In such cases, silver stain can be falsely negative, and immunohistochemical stains or electron microscopy should be used for diagnosis, if clinical suspicion of recurrence is high.

Pathology of Extrapulmonary Pneumocystosis

Extrapulmonary disease is seen primarily in patients with overwhelming pulmonary infection, those with severe underlying immunodeficiency, and those (particularly HIV-infected patients) who received aerosolized pentamidine for prophylaxis against PCP. Since 1982 there have been increasing reports of extrapulmonary dissemination of pneumocystis in AIDS patients receiving aerosol pentamidine. Sites of extrapulmonary dissemination include lymph nodes, skin, ears, eyes, bone marrow, spleen, liver, kidneys, thyroid gland, gastrointestinal tract, and a variety of other organs and tissues. The lesions of extrapulmonary pneumocystosis are gray-white or yellow nodules 0.5 to 4.9 mm or larger, and they resemble microabscesses. Histologically, the lesions are often angiocentric with eosinophilic foamy exudates similar to the ones seen in the lungs, and show abundant cyst forms on GMS stain. An inflammatory response is minimal or none, and when present it consists of histiocytes, lymphocytes, plasma cells, neutrophils, giant cells, and fibroblasts. In most cases the lesions gradually enlarge and contain all the developmental forms of pneumocystis, suggesting replication in anaerobic extrapulmonary sites. The characteristic morphology of the cysts on GMS stain and immunohistochemical stain is sufficient for making a diagnosis. Microscopically, the lesions consist of sheets of eosinophilic, foamy material identical to that described previously, composed of cysts and trophozoites, with little or no inflammatory response. Smaller lesions and satellite nodules may have an angiocentric distribution.

The ultrastructural pathology of PCP is mainly of pathogenetic interest. Ultrastructural studies have shown that the single or paired argyrophilic “intracystic bodies” are plaquelike thickenings of the cyst wall rather than sporozoites or other organelles. Such studies also have confirmed that *P. jiroveci* is strictly an extracellular pathogen. Trophozoites attach to the surface of type 1 pneumocytes by specialized interdigitations, without membrane fusion or communication between
Cytoplasmic compartments. Trophozoite attachment may eventually cause epithelial and endothelial damage, resulting in acute diffuse alveolar damage.

**Cytopathology of Pneumocystis Infection**

The cytologic features of PCP are well described and illustrated in the literature. Cytologic examination of induced sputum and BAL specimens has become the primary diagnostic modality for PCP, particularly in an HIV-infected patient population in whom the sensitivity of cytodiagnosis has been shown to be reasonably high. In Papanicolaou-stained smears, *P. jiroveci* is seen as aggregates of cysts and trophozoites with a granular, foamy, or honeycomb appearance (Fig. 13.20). These aggregates are usually spherical, with considerable depth of focus, and approximately the size of a normal alveolar sac. Sometimes referred to as “alveolar casts,” these aggregates can be recognized at screening magnification if present in sufficient quantity. However, the diagnosis should be confirmed with GMS stain. The honeycomb aggregates in Papanicolaou-stained smears are fluorescent when viewed with ultraviolet light and a fluorescence microscope; however, this method is no more sensitive or specific than GMS stain. Also, the fluorescent method is not readily available in all laboratories, especially in those in the developing world.

**Histologic Diagnosis of Pneumocystis jiroveci**

*Pneumocystis jiroveci* can be demonstrated by special histochemical, fluorescent, and immunohistochemical stains. The staining features of *P. jiroveci* are presented in Table 13.2. The easiest and most reliable stain is GMS, which stains the cysts in tissue sections, smears, and cytologic preparations. The cysts are round to oval, 4 to 7 μm in maximum dimension, and often have collapsed crescent and helmet forms, as seen in Figures 13.6 and 13.7. An intracystic density “central dot” or “paired comma structures” due to a plaque-like thickening of the cyst wall is an important diagnostic feature of pneumocystis. The alveolar foamy exudate is composed of trophozoites and sporozoites, which appear as basophilic dots on H&E-stained tissue sections, and can be seen in smears (but not tissue sections) by Romanowsky stains (Giemsa, Wright, Diff-Quick), and Gram and methylene blue stains.

Chemofluorescent techniques such as Calcofluor white highlight the cysts, but offer no advantage over GMS stain. *Pneumocystis jiroveci* pneumonia is not autofluorescent, unlike other fungi. Fluorescent antibody techniques, although specific, are time-consuming, require a fluorescent microscope, and do not allow visualization of morphologic details. A variety of monoclonal antibodies are available commercially to detect and confirm the identity of *P. jiroveci* in routinely processed biopsy and cytology specimens. These antibodies, which are specific and sensitive, identify both the cyst and trophozoite forms of *P. jiroveci*. For this reason, immunohistochemistry is considered to be more sensitive than GMS for the detection of *P. jiroveci* in clinical specimens. The immunostain is particularly useful for the examination of induced sputum and BAL specimens, which may contain abundant argyrophilic mucus and debris that can obscure the organisms, and for specimens from treated patients. An immunohistochemical stain provides a definitive diagnosis, and is more sensitive than GMS, especially in treated and extrapulmonary pneumocystis infection.
Differential Diagnosis

Although a large number of pathogenic microbes are stained with GMS, it is the yeast-like fungi, particularly *Histoplasma capsulatum*, *Candida glabrata*, and *Cryptococcus neoformans*, that are most difficult to distinguish from the cysts of *P. jiroveci*. The comparative features of these organisms are presented in Table 13.3. The recognition of the single or paired, comma-shaped argyrophilic foci in the walls of *P. jiroveci* cysts is most important, since structures with this configuration are never seen in the walls of yeast. Production of blastocidicida by the process of external budding is a characteristic feature of yeast, but the cysts of *P. jiroveci* do not reproduce by budding. *Cryptococcus neoformans* has a mucopolysaccharide capsule that is mucicarmine positive and Fontana-Masson (melanin) stain positive (even in the capsule deficient organisms), which distinguishes it from cysts of *P. jiroveci*. The yeast forms of *Candida* spp. are usually accompanied by mycelial elements (pseudo-hyphae and true hyphae), which are not a feature of pneumocystis.

The intracytoplasmic inclusions of cytomegalovirus (CMV) are argyrophilic in GMS-stained sections. However, they can be distinguished easily from pneumocystis cysts, because the viral inclusions are always located inside cells, and they “keep company” with typical Cowdry type A intranuclear inclusions, seen best in replicate sections stained with H&E. The cyst wall of *Toxoplasma gondii*, like that of *P. jiroveci*, is argyrophilic with GMS. The cysts of *T. gondii*, however, are many times larger than those of *P. jiroveci* and are clearly visible in H&E-stained sections, unlike the cysts of *P. jiroveci*. Finally, tissue elements such as leukocytes, erythrocytes, and mucous vacuoles are weakly argyrophilic and may complicate both screening and diagnosis in slides that are overstained with GMS. For this reason, a positive control slide known to contain cyst forms of *P. jiroveci* must be stained in parallel with unknown histologic sections and cytology smears, to gauge the intensity of silver staining.

Molecular Diagnosis of *Pneumocystis jiroveci*

Amplification of *P. jiroveci* DNA by PCR recently has been used for the diagnosis of *P. jiroveci* in induced sputum and BAL specimens, and reported to have greater sensitivity over standard methods (special stains and immunohistochemistry) for the detection of *P. jiroveci*. In a study of 29 patients with suspected PCP, PCR of *P. jiroveci* DNA in induced sputum was evaluated, and it was significantly more sensitive than cytology (54.5% positive versus 4.5% positive). A quantitative real-time PCR assay for detection and quantitation of *P. jiroveci* in 53 BAL specimens based on the probe targeting the gene encoding β-tubulin compared to immunofluorescence microscopic examination and Giemsa stain showed that all PCR-negative samples were negative by microscopy. Among the PCR-positive BAL specimens, only 35% were positive by microscopy. Polymerase chain reaction for detection of *P. jiroveci* appears to be a useful and noninvasive method that has high sensitivity and specificity for early diagnosis of PCP.

Confirmation Testing and Diagnosis

*Pneumocystis jiroveci* can be sustained in cell culture on a limited number of cell lines. To date, no artificial media support the growth of *P. jiroveci*. Serologic methods to detect antibodies to *P. jiroveci* are regarded as insensitive, mainly because many patients with PCP are unable to mount a detectable humoral response.
Therefore, demonstration of cysts or trophozoites with an appropriate special stain or by immunohistochemistry remains the only dependable way to establish the diagnosis of pneumocystosis.

Treatment

The prevention and treatment of pneumocystosis are rapidly evolving controversial subjects that are currently the focus of considerable investigational interest. Two standard drugs used to treat most patients with PCP are trimethoprim-sulfamethoxazole (TMP-SMX) and pentamidine isothionate. They appear to be equally effective and are associated with approximately the same incidence of adverse reactions, which may affect as many as 60% of patients with AIDS. Early adjunctive therapy with corticosteroids can reduce the morbidity and mortality associated with moderate or severe PCP.

Patients at high risk for PCP, specifically HIV-infected patients with CD4+ T-lymphocyte counts of less than 200 cells/mm³, and all AIDS patients who have already had one or more episodes of PCP received prophylaxis with TMP-SMX and aerosolized pentamidine. The latter regimen, however, may predispose to extrapulmonary pneumocystosis.

The recent introduction of combination antiretroviral therapy, including HAART, have contributed to the reduced incidence of PCP. An investigational drug, 566CB0, used in mild to moderately severe episodes of PCP in AIDS patients has shown promising results. Other drugs under development include echinocandins and pneumocandins, which inhibit β-glucan synthesis, or sordarins, which inhibit fungal protein synthesis.

References

1. Levine SJ. Pneumocystis carinii. Clin Chest Med 1996; 17:665–695.
2. Catterall JR, Potasman I, Remington JS. Pneumocystis carinii pneumonia in the patient with AIDS. Chest 1985; 88:758–762.
3. Centers for Disease Control: Kaposi's sarcoma and pneumocystis pneumonia among homosexual men—New York City and California. MMWR 1981;30:305–308.
4. Sepkowitz KA. Opportunistic infections in patients with and without acquired immunodeficiency syndrome. Clin Infect Dis 2002;34:1098–1107.
5. HIV/AIDS surveillance report. Vol. 9, no. 3. Atlanta: Centers for Disease Control and Prevention, 2003:1–20.
6. Walzer PD, Perl DP, Krogstad DJ, et al. Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features. Ann Intern Med 1974;80: 83–93.
7. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984;100: 663–671.
8. Chagas C. Nova tripanozomiae humana: estudio sobre a morfologia e o evolution do Schizotrypanum cruzi n. gen., n. sp., agente etiojiico de nova entidade morbida do homem. Mem Inst Oswaldo Cruz 1909;1:159–218.
9. Carinii A. Formas de eschizogonia do Trypanozoma lewisi. Commun Soc Med Sao Paolo 1910;16:204.
10. Delanoë P, Delanoë M. Sur les rapports des kystes de carinii du poumon des rats avec le Trypanosoma Lewisi. C R Acad Sci 1912;155:658–660.
11. Dutz W. Pneumocystis carinii pneumonia. Pathol Annu 1970;5:309–341.
12. Van der Meer G, Brug SL. Infection par Pneumocystis chez l’homme et chez les animaux. Ann Soc Belg Med Trop 1942;22:301–307.
13. Armengol CE. A historical review of pneumocystis carinii. JAMA 1995;273:750–751.
14. Mills J. Pneumocystis carinii and Toxoplasma gondii infections in patients with AIDS. Rev Infect Dis 1986;8: 1001–1011.
15. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 2002;8:891–896.
16. Edman JC, Kovacs JA, Masur H, et al. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988;334:519–522.
17. Stringer SL, Hudson K, Blasé MA, et al. Sequence from ribosomal RNA of Pneumocystis carinii compared to those of four fungi suggests an ascomycetous affinity. J Protozool 1989;36:145–165.
18. Bedrossian CWM. Rapid cytologic diagnosis of Pneumocystis: a comparison of effective techniques. Semin Diag Pathol 1989;6:245–261.
19. Vavra J, Kucera K. Pneumocystis carinii, its ultrastructure and ultrastructural affinities. J Protozool 1970;17:463–483.
20. Sheldon WH. Experimental pulmonary Pneumocystis carinii infection in rabbits. J Exp Med 1959;110:147–160.
21. Copland JW. Canine pneumonia caused by Pneumocystis carinii. Aust Vet J 1974;50:515–518.
22. McConnell EE, Basson PA, Pienaar JD. Pneumocystis in domestic goat. Onderstepoort J Vet Res 1971;38:117–124. (Hughes WT. Pneumocystis carinii pneumonia. Vol. 1. Boca Raton, Fla.: CRC Press; 1987.)
23. Siebold HR, Munnell JF. Pneumocystis in a pig. Vet Pathol 1977;14:89.
24. Settines OP, Hasselager E. Occurrence of Pneumocystis carinii in Delanoe & Delanoe, 1912 in dogs and cats in Denmark. Nord Vet Med 1984;36:179–181.
25. Chandler FW, McClure HM, Campbell WG, Watts JC. Pulmonary pneumocystosis in nonhuman primates. Arch Pathol Lab Med 1976;100:163–167.
26. Long GG, White JD, Stookey JL. Pneumocystis carinii infection in splenectomized owl monkeys. J Am Vet Med Assoc 1975;167:651–654.
27. Gigliotti F, Harmsen AG, Haidaris CG, Haidiris PJ. Pneumocystis carinii is not universally transmissible between mammalian species. Infect Immun 1993;61:2886–2890.
28. Thomas CF J., Limper AH. Medical progress: Pneumocystis pneumonia (review article). N Engl J Med 2004;350: 2487–2498.
29. Wazir JF, Ansari NA. Pneumocystis carinii infection. Update and review. Arch Pathol Lab Med 2004;128: 1023–1027.
30. Hughes WT. Natural mode of acquisition for de novo infection with Pneumocystis carinii. J Infect Dis 1982;145: 842–848
31. Hughes WT, Bartley DL, Smith BM. A natural source of infection due to Pneumocystis carinii. J Infect Dis 1983; 147:595.
32. Hendley JO, Weller TH. Activation and transmission in rats of infection with Pneumocystis carinii. Proc Soc Exp Biol Med 1971;137:1401–1404.
33. Walzer PD, Schnelle V, Armstrong D, Rosen PP. The nude mouse: a new experimental model for Pneumocystis carinii infection. Science 1977;197:177–179.
34. Levine SJ. Pneumocystis carinii. Pulmonary complications of HIV infection. Clin Chest Medicine 1996;17:665–695.
35. Bartlett M, Cushion MT, Fishman JA, et al. Revised nomenclature for Pneumocystis carinii. J Eukaryotic Microbiol 1994;41:121S.
36. Gagliotti F, Haidaris PJ, Haidaris CG, et al. Further evidence of host species-specific variation in antigens of Pneumocystis carinii using the polymerase chain reaction. J Infect Dis 1993;168:191–194.
37. Smulian AG, Walzer PD. The biology of Pneumocystis carinii. CRC Crit Rev Microbiol 1992;18:191–216.
38. Hughes WT, ed. Pneumocystis carinii pneumonia. 2nd ed. New York: Marcel Dekker; 1994:123.
39. Vargas SI, Hughes WT, Santolaya ME, et al. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin Infect Dis 2001;32:855–861.
40. Peters SE, Wakefield AE, Sinclair K, et al. A search for P. carinii in postmortem lungs by DNA amplification. J Pathol 1992;166:195–198.
41. Wakefield AE, Pixley FJ, Banerji S, et al. Detection of Pneumocystis carinii with DNA amplification. Lancet 1990;336:451–453.
42. Vargas SI, Hughes WT, Wakefield AE, et al. Limited persistence in and subsequent elimination of pneumocystis carinii from the lungs after P. carinii pneumonia. J Infect Dis 1995;172:506–510.
43. Cushion MT, Stringer JR, Walzer PD. Cellular and molecular biology of Pneumocystis carinii. Int Rev Cytol 1991; 131:59–107.
44. Sepkowitz K, Schlenger N, Godwin T, et al. DNA amplification in experimental Pneumocystosis: characterization of serum Pneumocystis carinii DNA and potential P. carinii carrier states. J Infect Dis 1993;168:421–426.
45. Chave JP, David S, Wauters JP, et al. Transmission of Pneumocystis carinii from AIDS patients to other immunosuppressed patients: a cluster of Pneumocystis carinii pneumonia in renal transplant patients. AIDS 1991;5:927–932.
46. Chusid MJ, Heyrman KA. An outbreak of Pneumocystis carinii pneumonia at a pediatric hospital. Pediatrics 1978; 62:1031–1035.
47. Ruebas TK II, Weinstein RA, Baekner RL, et al. An outbreak of Pneumocystis pneumonia in children with acute lymphocytic leukemia. Am J Dis Child 1978;132: 143–148.
48. Santiago-Delpin EA, Mora E, Gonzalez ZA, et al. Factors in an outbreak of Pneumocystis carinii in a transplant unit. Transplant Proc 1988;20:462–465.
49. Singer C, Armstrong D, Rosen PP, et al. Pneumocystis carinii pneumonia: a cluster of eleven cases. Ann Intern Med 1975;82:772–777.
50. Peglow SL, Smulian GA, Linke MJ, et al. Serologic responses to specific Pneumocystis carinii antigens in health and disease. J Infect Dis 1990;161:296–306.
51. Smulian AG, Linke MJ, Baughman RP, et al. Characterization of Pneumocystis carinii antigen in bronchoalveolar lavage fluid by Western blot. Unpublished observations.
52. Ma L, Jia Q, Kovacs JA. Development of a yeast assay for rapid screening of inhibitors of human-derived Pneumocystis carinii dihydrofolate reductase. Antimicrob Agents Chemother 2002;46:3101–3103.
53. Kovacs JA, Powell F, Edman JC, et al. Multiple genes encode the major surface glycoprotein of Pneumocystis carinii. J Biol Chem 1992;268:6034–6040.
54. Barton EG Jr, Campbell WG Jr. Further observations on the ultrastructure of Pneumocystis. Arch Pathol 1967;83: 527–534.
55. Barton EG Jr, Campbell WG Jr. Pneumocystis carinii in lungs of rats treated with cortisone acetate: ultrastructural observations relating to the life cycle. Am J Pathol 1969; 54:209–236.
56. Campbell WG Jr. Ultrastructure of Pneumocystis in human lung: life cycle in human pneumocystosis. Arch Pathol 1972;93:312–324.
13. Pneumocystis jiroveci Pneumonia

65. Bedrossian CWM. Ultrastructure of Pneumocystis carinii: a review of internal and surface characteristics. Semin Diagn Pathol 1989;6:212–237.

66. Matsumoto Y, Yoshida Y. Sporogony in Pneumocystis carinii: synaptonemal complexes and meiotic nuclear divisions observed in precysts. J Protozool 1984;31:420–428.

67. Hasleton PS, Curry A, Rankin EM. Pneumocystis carinii pneumonia: a light microscopical and ultrastructural study. J Clin Pathol 1981;34:1118–1146.

68. Cushion MT, Ruffolo JJ, Walzer PD. Analysis of the developmental stages of Pneumocystis carinii, in vitro. Lab Invest 1988;58:324–331.

69. Garrison RG, Arnold WM. Atlas of cell morphology. In: Arnold WN, ed. Yeast cell envelopes: biochemistry, biophysics, and ultrastructure. Vol. 1. Boca Raton, FL: CRC Press, 1981:5.

70. Zierdt CH. Studies of Blastocystis hominis. J Protozool 1973;20:114–121.

71. Yokishawa H, Tegoshi T, Yoshida YY. Detection of surface carbohydrates on Pneumocystis carinii by fluorescein-conjugated lectins. Parasitol Res 1987;74:43–49.

72. Kaneshiro ES, Cushion MT, Walzer PD, et al. Analyses of Pneumocystis fatty acids. J Protozool 1989;36:55S–57S.

73. Matsumoto Y, Matsuda S, Tegoshi T. Yeast glucan in the cyst wall of Pneumocystis carinii. J Protozool 1989;36:21S–22S.

74. Linke MJ, Cushion MT, Walzer PD. Properties of the major rat and human Pneumocystis carinii antigens. Infect Immun 1989;57:1547–1555.

75. Yoshikawa H, Morioka H, Yoshida Y. Ultrastructural detection of carbohydrates in the pellicle of Pneumocystis carinii. Parasitol Res 1988;74:537–543.

76. Dei-Cas E, Soulez B, Camus D. Ultrastructural study of Pneumocystis carinii in explant cultures of rabbit lung and in cultures with and without feeder cells. J Protozool 1989;36:55S–57S.

77. Vossen MEMH, Beckers PJA, Meuwissen JEH Th, et al. Developmental biology of Pneumocystis carinii, an alternative view on the life cycle of the parasite. Z Parasitenkd 1978;55:101–118.

78. Watts JC, Chandler FW. Pneumocystis carinii pneumonitis: the nature and diagnostic significance of the methenamine silver-positive “intracystic bodies.” Am J Surg Pathol 1985;9:744–751.

79. Mahan CT, Sale GE. Rapid methenamine silver stain for Pneumocystis and fungi. Arch Pathol Lab Med 1978;102:351–352.

80. Pintozzi RL. Modified Grocott’s methenamine silver nitrate method for quick staining of Pneumocystis carinii. J Clin Pathol 1978;31:803–805.

81. Musto L, Flanigan MJ, Elbadawi A. Ten-minute silver stain for Pneumocystis carinii and fungi in tissue sections. Arch Pathol Lab Med 1982;106:292–294.

82. Brinn NT. Rapid metallic histological staining using the microwave oven. J Histotechnol 1983;6:125–129.

83. Shimono LH, Hartman B. A simple and reliable rapid methenamine silver stain for Pneumocystis carinii and fungi. Arch Pathol Lab Med 1986;110:855–856.

84. Lundgren B, Cotton R, Lundgren JD, et al. Identification of Pneumocystis carinii chromosomes and mapping of five genes. Infect Immun 1990;58:1705–1710.

85. Hong ST, Steele PE, Cushion MT, et al. Pneumocystis carinii karyotypes. J Clin Microbiol 1990;28:1785–1795.

86. Stringer SL, Stringer JR, Blasé MA, et al. Pneumocystis carinii: sequence from ribosomal RNA implies a close relationship with fungi. Exp Parasitol 1989;68:450–461.

87. Edman U, Edman JC, Lundgren B, et al. Isolation and expression of Pneumocystis carinii thymidylate synthase gene. Proc Natl Acad Sci USA 1989;86:6503–6507.

88. Yoshikawa H, Edman U, Cao M, Lundgren B, Kovacs JA, Santi DV. Isolation and expression of the Pneumocystis carinii dihydrofolate reductase gene. Proc Natl Acad Sci USA 1989;86:8625–8629.

89. Latouche S, Lacube P, Maury E, et al. Pneumocystis jiroveci dihydropteroate synthase genotypes in French patients with pneumocystosis: a 1998–2001 prospective study. Med Mycology 2003;41:533–537.

90. Crothers K, Beard CB, Turner J, et al. Severity and outcome of HIV-associated pneumocystis pneumonia containing Pneumocystis jiroveci dihydropteroate synthase gene mutations. AIDS 2005;19:801–805.

91. Kazanjian PH, Fisk D, Armstrong W, et al. Increase in prevalence of Pneumocystis carinii mutations in patients with AIDS and P. carinii pneumonia, in the United States and China. J Infect Dis 2004;189:1684–1687.

92. Matos O, Lee CH, Jin S, et al. Pneumocystis jiroveci in Portuguese immunocompromised patients: association of specific ITS genotypes with treatment failure, bad clinical outcome and childhood. Int J Evol 2003;3:281–285.

93. Graves DC, McNabb SJN, Ivey MH, Worley MA. Development and characterization of monoclonal antibodies to Pneumocystis carinii. Infect Immun 1986;51:125–133.

94. Kovacs JA, Halpern JL, Swan JC, et al. Identification of antigens and antibodies specific for Pneumocystis carinii. J Immunol 1988;140:2023–2031.

95. Walzer PD, Linke MJ. A comparison of the antigenic characteristics of rat and human Pneumocystis carinii by immunoblotting. J Immunol 1987;138:2257–2265.

96. Kovacs JA, Halpern JL, Lundgren B, et al. Monoclonal antibodies to Pneumocystis carinii: identification of specific antigens and characterization of antigenic differences between rat and human isolates. J Infect Dis 1989;159:60–70.

97. Meuwissen JHE, Tauber I, Leenewber ADEM, et al. Parasitologic and serologic observations of infection with Pneumocystis in humans. J Infect Dis 1977;136:43–49.

98. Masur H, Jones TC. The interaction in vitro of Pneumocystis carinii with macrophages and L-cells. J Exp Med 1978;147:157–170.

99. Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type I. N Engl J Med 1990;322:161–165.
101. Afessa B, Green W, Chiao J, et al. Pulmonary complications of HIV infection: autopsy findings. Chest 1998;113:1225-1229.

102. Gigliotti F, Stokes DC, Cheatham AB, et al. Development of murine monoclonal antibodies to Pneumocystis carinii. J Infect Dis 1986;154:315-322.

103. Vuk-Pavlovic Z, Standing JE, Crouch EC, et al. Carbohydrate recognition domain of surfactant protein D mediates interactions with Pneumocystis carinii glycoprotein A. Am J Resp Cell Mol Biol 2001;24:475-484.

104. O'Riordan DM, Standing JE, Limper AH. Pneumocystis carinii glycoprotein A binds macrophage mannose receptors. Infect Immun 1995;63:779-784.

105. Kottom TJ, Limper AH. Cell wall assembly by Pneumocystis carinii: evidence for a unique gsc-1 subunit mediating beta-1,3-glucan deposition. J Biol Chem 2000;275:40628-40634.

106. Schmatz DM, Romancheck MA, Pittarelli LA, et al. Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors. Proc Natl Acad Sci USA 1990;87:5950-5954.

107. Powles MA, Liberator P, Anderson J, et al. Efficacy of MK-40634, a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Lab Invest 1986;54:589-592.

108. Vassallo R, Standing JE, Limper AH. Isolated Pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses. J Immunol 2000;164:3755-3763.

109. Hahn PY, Evans SE, Kottom TJ, Standing JE, Pagano RE, Limper AH. Pneumocystis carinii cell wall beta-glucan induces release of macrophage inflammatory protein-2 from alveolar epithelial cells via a lactosylceramide-mediated mechanism. J Biol Chem 2003;278:2043-2050.

110. Thomas CF, Anders RA, Gustafson MP, et al. Pneumocystis carinii contains a functional cell-division-cycle Cdc2 homologue. Am J Respir Cell Mol Biol 1998;18:297-306.

111. Gustafson MP, Thomas CF Jr, Rusnak F, et al. Differential regulation of growth and checkpoint control mediated by a Cdc25 mitotic phosphatase from Pneumocystis carinii. J Biol Chem 2001;276:835-843.

112. Kottom TJ, Thomas CF Jr, Mubarak KK, et al. Pneumocystis carinii uses a functional cdc13 B-type cyclin complex during its life cycle. Am J Respir Cell Mol Biol 2000;22:722-731.

113. Vohra PK, Puri V, Thomas CF Jr. Complementation and characterization of the Pneumocystis carinii MAPK, PCM. FEBS Lett 2003;551:139-146.

114. Kottom TJ, Kohler JR, Thomas CF Jr, et al. Lung epithelial cells and extracellular matrix components induce expression of Pneumocystis carinii STE20, a gene complementing the mating and pseudohyphal growth defects of STE20 mutant yeast. Infect Immun 2003;71:6463-6471.

115. Vohra PK, Puri V, Kottom TJ, et al. Pneumocystis carinii STE11, an HMG-box protein, is phosphorylated by the mitogen activated protein kinase PCM. Gene 2003;312:173-179.

116. Smulian AG, Sesterhenn T, Tanaka R, et al. The ste3 pheromone receptor gene of Pneumocystis carinii is surrounded by a cluster of signal transduction genes. Genetics 2001;157:991-1002.

117. Morales JJ, Vohra PK, Puri V, et al. Characterization of a lanosterol 14 alpha-demethylase from Pneumocystis carinii. Am J Respir Cell Biol 2003;29:232-238.

118. Kaneshiro ES, Rosenfeld JA, Basellin-Eweida M, et al. The Pneumocystis carinii drug target S-adenosyl-L-methionine:sterol C-24 methyl transferase has a unique substrate preference. Mol Microbiol 2002;44:989-999.

119. Walzer PD. Attachment of microbes to host cells: relevance of Pneumocystis carinii. Lab Invest 1986;54:589-592.

120. Limper AH, Standing JE, Hoffman OA, Castro M, Neese LW. Vitronecin binds to Pneumocystis carinii and mediates organism attachment to cultured lung epithelial cells. Infect Immun 1993;61:4302-4309.

121. Beck JM, Preston AM, Wagner JG, et al. Interaction of rat Pneumocystis carinii and rat alveolar epithelial cells in vitro. Am J Physiol 1998;275:L118-L125.

122. Limper AH, Edens M, Anders RA, et al. Pneumocystis carinii inhibits cyclin-dependent kinase activity in lung epithelial cells. J Clin Invest 1998;101:1148-1155.

123. O'Riordan DM, Standing JE, Kwon KY, et al. Surfactant protein D interacts with Pneumocystis carinii and mediates organism adherence to alveolar macrophages. J Clin Invest 1995;95:2699-2710.

124. Beers MF, Atochina EN, Preston AM, et al. Inhibition of lung surfactant protein B expression during Pneumocystis carinii pneumonia in mice. J Lab Clin Med 1999;133:423-433.

125. Williams MD, Wright JR, March KL, et al. Human surfactant protein A enhances attachment of Pneumocystis carinii to rat alveolar macrophages. Am J Respir Cell Mol Biol 1996;14:232-238.

126. Koziel H, Phelps DS, Fishman JA, et al. Surfactant protein A reduces binding and phagocytosis of Pneumocystis carinii by human alveolar macrophages in vitro. Am J Respir Cell Mol Biol 1998;18:834-843.

127. Yong SJ, Vuk-Pavlovic Z, Standing JE, et al. Surfactant protein D-mediated aggregation of Pneumocystis carinii impairs phagocytosis by alveolar macrophages. Infect Immun 2003;71:1662-1671.

128. Wright TW, Notter RH, Wang Z, et al. Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia. Infect Immun 2001;69:758-764.

129. Gigliotti F, Hughes WT. Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models. J Clin Invest 1988;81:1666-1668.

130. Shellito J, Suzara VV, Blumenfeld W, et al. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. J Clin Invest 1990;85:1686-1693.

131. Beck JM, Harmsen AG. Lymphocytes in host defense against Pneumocystis carinii. Semin Respir Infect 1998;13:330-338.

132. Wright TW, Johnston CJ, Harmsen AG, et al. Chemokine gene expression during Pneumocystis carinii-driven pulmonary inflammation. Infect Immun 1999;67:3452-3460.

133. Beck JM, Liggitt HD, Brunette EN, et al. Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon. Infect Immun 1991;59:3859-3862.
13. Pneumocystis jiroveci Pneumonia

134. Downing JF, Kachel DL, Pasula R, et al. Gamma interferon stimulates rat alveolar macrophages to kill Pneumocystis carinii by L-arginine- and tumor necrosis factor-dependent mechanisms. Infect Immun 1999;67:1347–1352.

135. Ezekowitz RA, Williams DJ, Koziel H, et al. Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor. Nature 1991;351:155–158.

136. Limper AH, Hoyte JS, Standing JE. The role of macrophages in Pneumocystis carinii degradation and clearance from the lung. J Clin Invest 1997;99:2110–2117.

137. Koziel H, Eichbaum Q, Kruskal BA, et al. Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor down regulation. J Clin Invest 1998;102:1332–1344.

138. Vassallo R, Kottom TJ, Standing JE, et al. Vitronectin and fibronectin function as glucan binding proteins augmenting macrophage responses to Pneumocystis carinii. Am J Respir Cell Mol Biol 2001;25:203–211.

139. Brown GD, Gordon S. Immune recognition: a new receptor for beta-glucans. Nature 2001;413:36–37.

140. Hoffman OA, Standing JE, Limper AH. Pneumocystis carinii stimulates tumor necrosis factor-alpha release from alveolar macrophages through a beta-glucan-mediated mechanism. J Immunol 1993;150:3932–3940.

141. Chen W, Havell EA, Harmsen AG. Importance of endogenous tumor necrosis factor alpha and gamma interferon in host resistance against Pneumocystis carinii infection. Infect Immun 1992;60:1279–1284.

142. Benfield TL, Vestbo J, Junge J, et al. Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1995;151:1058–1062.

143. Dutz W, Post C, Vessal K, et al. Endemic infantile Pneumocystis carinii infection: the Shiraz study. Natl Cancer Inst Monogr 1976;43:31–38.

144. Dutz W. Pneumocystis carinii infection and interstitial plasma cell pneumonia: what does history teach? Semin Diagn Pathol 1989;6:195–202.

145. Hughes WT. Pneumocystis carinii pneumonitis. Chest 1984;85:810–813.

146. Burke BA, Good RA. Pneumocystis carinii infection. Medicine (Baltimore) 1973;52:23–51.

147. Sepkowitz KA, Brown AE, Telzak EF, et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992;267:832–837.

148. Levine SJ, Masur H, Gil FJ, et al. Effect of aerosolized pentamidine prophylaxis on the diagnosis of Pneumocystis carinii pneumonia by induced sputum examination in patients infected with the human immunodeficiency virus. Am Rev Respir Dis 1991;144:760–764.

149. Moe AA, Hardy WD. Pneumocystis carinii infection in the HIV-seropositive patient. Infect Dis Clin North Am 1994;8:331–364.

150. Hopewell PC. Pneumocystis carinii pneumonia: diagnosis. J Infect Dis 1988;6:115–119.

151. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med 1993;329:1922–1926.

152. Jacobson LP, Kirby AJ, Polk S, et al. Changes in survival after acquired immunodeficiency syndrome (AIDS): 1984–1991. Am J Epidemiol 1993;138:952–964.

153. Hughes WT. Natural mode of acquisition for de novo infection with Pneumocystis carinii. J Infect Dis 1982;145:842–848.

154. Montaner JSG, Le T, Hogg R, et al. The changing spectrum of AIDS index diseases in Canada. AIDS 1994;8:693–696.

155. Munoz A, Schrager LK, Bacellar H, et al. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the multicenter AIDS cohort study: 1985–1991. Am J Epidemiol 1993;137:423–438.

156. Smith E, Orholm MK. Danish AIDS patients 1988–1993: a recent decline in Pneumocystis carinii pneumonia as AIDS-defining disease related to the period of known HIV positivity. Scand J Infect Dis 1994;26:517–522.

157. Wall PG, Porter K, Noone A, et al. Changing incidence of Pneumocystis carinii pneumonia as initial AIDS defining disease in the United Kingdom. AIDS 1993;7:1523–1525.

158. Jacobs JL, Libby DM, Winters RA, et al. A cluster of Pneumocystis carinii pneumonia in adults without predisposing illnesses. N Engl J Med 1991;324:246–250.

159. Catterall JR, Potasman I, Remington JS. Pneumocystis carinii pneumonia in the patient with AIDS. Chest 1985;88:758–762.

160. Engelberg LA, Lerner CW, Tapper ML. Clinical features of Pneumocystis pneumonia in the acquired immune deficiency syndrome. Am Rev Respir Dis 1984;130:689–694.

161. Gottlieb MS. Pulmonary disease in the acquired immune deficiency syndrome. Chest 1984;86:29S–31S.

162. Kales CP, Murren JR, Torres RA, et al. Early predictors of in-hospital mortality for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Arch Intern Med 1987;147:1413–1417.

163. Ognibene FP, Shelhamer J, Gill V, et al. The diagnosis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome using subsegmental bronchoalveolar lavage. Am Rev Respir Dis 1984;129:929–32.

164. Sterling RP, Bradley BB, Khalil KG, et al. Comparison of biopsy-proven Pneumocystis carinii pneumonia in acquired immune deficiency syndrome patients and renal allograft recipients. Ann Thorac Surg 1984;38:494–499.

165. Wollschlager CM, Khan FA, Chitkara RK, et al. Pulmonary manifestations of the acquired immunodeficiency syndrome (AIDS). Chest 1984;85:197–202.

166. Limper AH, Offord KP, Smith TF, et al. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989;140:1204–1209.

167. Gold JW. Clinical spectrum of infections in patients with HTLV-III-associated diseases. Cancer Res 1985;45:4652s–4654s.

168. Curtis J, Goodman P, Hopewell PC. Non-invasive tests in the diagnostic evaluation of Pneumocystis carinii pneumonia in patients with or suspected of having AIDS. Am Rev Respir Dis 1986;133:A182.

169. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998;113:1215–1224.
170. Leoung GS, Feigal DW, Montgomery AB, et al. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community Prophylaxis Trial. N Engl J Med 1990;323:769–775.

171. Dembinski AS, Smith DM, Goldsmith JC, Woods GL. Widespread dissemination of Pneumocystis carinii infection causing extrapulmonary organ failure: clinical, pathologic, and immunohistochemical analysis. Mod Pathol 1990;3:25–31.

172. Ravinglione MC. Extrapulmonary pneumocystosis: the first 50 cases. Rev Infect Dis 1990;12:1127–1138.

173. Telazak EE, Armstrong D. Extrapulmonary infection and other unusual manifestations of Pneumocystis carinii. In: Walzer PD, ed. Pneumocystis carinii pneumonia. 2nd ed. New York: Marcel Dekker, 1994:361.

174. Telazak EE, Cote RJ, Gold JW, et al. Extrapulmonary Pneumocystis carinii infections. Rev Infect Dis 1990;12:380–386.

175. Davey RT, Margolis D, Kleiner D, et al. Digital necrosis and disseminated Pneumocystis carinii infection after aerosolized pentamidine prophylaxis. Ann Intern Med 1989;111:681–682.

176. Feuerstein IM, Francis P, Raffeld M, et al. Widespread visceral calcifications in disseminated Pneumocystis carinii infection: CT characteristics. J Comput Assist Tomogr 1990;14:149–151.

177. Koval CE, Gigliotti F, Nevis D, et al. Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection. Clin Infect Dis 2002;35:491–493.

178. Barry SM, Lipman MC, Deery AR, et al. Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV-infected subjects. HIV Med 2002;3: 207–211.

179. Price RA, Hughes WT. Histopathology of Pneumocystis carinii infection and infection in malignant disease in childhood. Hum Pathol 1974;5:737–752.

180. Gal AA, Koss MN, Strigel S, Angritt P. Pneumocystis carinii infection in the acquired immunodeficiency syndrome. Semin Diagn Pathol 1989;6:287–299.

181. Watts JC, Chandler FW. Pneumocystis carinii pneumonia: the nature and diagnostic significance of methenamine silver-positive “intracystic bodies.” Am J Surg Pathol 1985; 9:744–751.

182. Travis WD. Pathologic features. In: Walzer PD, ed. Pneumocystis carinii pneumonia. 2nd ed. New York: Marcel Dekker; 1994:155.

183. Travis WD, Pittaluga S, Lipschik GY, et al. Atypical pathologic manifestations of Pneumocystis carinii pneumonia in the acquired immune deficiency syndrome. Review of 123 lung biopsies from 76 patients with emphasis on cysts, vascular invasion, vasculitis, and granulomas. Am J Surg Pathol 1990;14:615–625.

184. Saltzblatt MJ, Prices JM. Pulmonary pathology in AIDS: atypical Pneumocystis carinii infection and lymphoid interstitial pneumonia. Thorax 1994;49:S46–55.

185. Weber WR, Askin FB, Debener LP. Lung biopsy in Pneumocystis carinii pneumonia: a histopathologic study of typical and atypical features. Am J Clin Pathol 1977;67: 11–19.

186. Saltzblatt MJ, Mones JM. Cavitary and other atypical manifestations of Pneumocystis carinii pneumonia. Semin Diagn Pathol 1989;6:273–286.

187. Askin FB, Katzenstein ALA. Pneumocystis infection masquerading as diffuse alveolar damage: a potential source of diagnostic error. Chest 1981;70:420–422.

188. Nash G, Fligiel S. Pathologic features of the lung in the acquired immune deficiency syndrome (AIDS): an autopsy study of seventeen homosexual males. Am J Clin Pathol 1984;81:6–12.

189. Adegboyega PA, Adesokan A, Haque AK. A clinicopathologic study of adult respiratory distress syndrome in human immunodeficiency virus-infected patients. Am J Clin Pathol 1997;107(4):471.

190. Liu YC, Tomaszewski JF Jr, Tomford JW, et al. Necrotizing Pneumocystis carinii vasculitis associated with lung necrosis and cavitation in a patient with acquired immunodeficiency syndrome. Arch Pathol Lab Med 1989;113:494–497.

191. Feuerstein IM, Archer A, Plada JM, et al. Thin-walled cavities, cysts and pneumothorax in Pneumocystis carinii
pneumonia: further observations with histopathologic correlation. Radiology 1990;174: 696–702.

204. Lee MM, Schinella RA. Pulmonary calcification caused by Pneumocystis carinii pneumonia. A clinicopathological study of 13 cases in acquired immune deficiency syndrome patients. Am J Surg Pathol 1991;15:376–380.

205. Bleiweiss IJ, Jagirdar JS, Klein MJ, et al. Granulomatous Pneumocystis carinii pneumonia in three patients with the acquired immune deficiency syndrome. Chest 1988;94: 580–583.

206. Blumenfeld W, Basgoz N, Owen WF Jr, Schmidt DM. Granulomatous pulmonary lesions in patients with the acquired immunodeficiency syndrome (AIDS) and Pneumocystis carinii infection. Ann Intern Med 1988;109:505–507.

207. Bondoc AY, White DA. Granulomatous Pneumocystis carinii pneumonia in patients with malignancy. Thorax 2002;57:435–437.

208. Gal AA, Plummer AL, Langston AL, et al. Granulomatous Pneumocystis carinii pneumonia complicating hematopoietic cell transplantation. Pathol Res Pract 2002;198: 553–558.

209. Cupples JB, Blackie SP, Road JD. Granulomatous Pneumocystis carinii pneumonia mimicking tuberculosis. Arch Pathol Lab Med 1989;113:1281–1284.

210. Hartz JW, Geisinger KR, Scharyj M, Muss HB. Granulomatous pneumocystosis presenting as a solitary pulmonary nodule. Arch Pathol Lab Med 1985;109:466–469.

211. Halton SK, Krivisky B, Leonidas J. Pneumocystis carinii pneumonia presenting as a single pulmonary nodule. Pediatr Radiol 1986;16:59–60.

212. Afessa B, Green WR, Williams WA, et al. Pneumocystis carinii pneumonia complicated by lymphadenopathy and pneumothorax. Arch Intern Med 1988;148:2651–2654.

213. Saldana MJ, Mones JM, Martinez FR. The pathology of treated Pneumocystis carinii infection and lymphoid interstitial pneumonia. Thorax 1994;49:546–55.

214. El-Sadr W, Sidhu G. Persistence of trophozoites after successful treatment of Pneumocystis carinii pneumonia. Ann Intern Med 1986;105:889–890.

215. Hardy WD, Northfelt DW, Drake TA. Fatal, disseminated pneumocystosis in a patient with acquired immunodeficiency syndrome receiving prophylactic aerosolized pentamidine. Am J Med 1989;87:329–331.

216. Long EG, Smith JS, Meier J. Attachment of Pneumocystis carinii to rat pneumocytes. Lab Invest 1986;54:609–615.

217. Itatani CA, Marshall GJ. Ultrastructural morphology and staining characteristics of Pneumocystis carinii in situ and from bronchoalveolar lavage. J Parasitol 1988;74:700–712.

218. Yoneda K, Walzer PD. Mechanism of pulmonary alveolar injury in experimental Pneumocystis carinii pneumonia in the rat. Br J Exp Pathol 1981;62:339–346.

219. Greaves TS, Strigel SM. The recognition of Pneumocystis carinii in Papanicolaou-stained smears. Acta Cytol 1985;29: 714–720.

220. Bedrossian CWM, Mason MF, Gupta PK. Rapid cytologic diagnosis of Pneumocystis: a comparison of effective techniques. Semin Diagn Pathol 1989;6:245–261.

221. Ghali VS, Garcia RL, Skolom J. Fluorescence of Pneumocystis carinii in Papanicolaou smears. Hum Pathol 1984;15: 907–909.

222. Kim YK, Parulekar S, Yu P, et al. Evaluation of calcofluor white stain for detection of Pneumocystis carinii. Diagn Microbiol Infect Dis 1990;13:307–310.

223. Watts JC, Chandler FW. Pneumocystosis. In: Connors DH, Chandler FW, et al., eds. Pathology of infectious diseases. Stamford, CT: Appleton & Lange; 1997:1241–1251.

224. Fraire AE, Kemp B, Greenberg SD, et al. Calcofluor white stain for the detection of Pneumocystis carinii in transbronchial lung biopsy specimens: a study of 68 cases. Mod Pathol 1996;9:861–864.

225. Baughman RP, Strohofer SS, Clinton BA, et al. The use of an indirect fluorescent antibody test for detecting Pneumocystis carinii. Arch Pathol Lab Med 1989;113: 1062–1065.

226. Linder J, Radio SJ. Immunohistochemistry of Pneumocystis carinii. Semin Diagn Pathol 1989;6:238–244.

227. Midgley J, Parsons PA, Shanson DC, et al. Monoclonal immunofluorescence compared with silver stain for investigating Pneumocystis carinii pneumonia. J Clin Pathol 1991;44:75–76.

228. Homer KS, Wiley WL, Smith AL, et al. Monoclonal antibody to Pneumocystis carinii: comparison with silver stain in bronchial lavage specimens. Am J Clin Pathol 1992;97: 619–624.

229. Amin MB, Metzger E, Zarbo RJ. Detection of Pneumocystis carinii: comparative study of monoclonal antibody and silver staining. Am J Clin Pathol 1992;98:13–18.

230. Nayar R, Tabbara SO. Detecting Pneumocystis carinii by immunohistochemistry. Lab Med 1996;27:547–550.

231. Radio SJ, Hansen S, Goldsmith J, Linden J. Immunohistochemistry of Pneumocystis carinii infection. Mod Pathol 1990;3:462–469.

232. Gorelkin L, Chandler FW, Ewing EP. Staining qualities of cytomegalovirus inclusions in the lungs of patients with the acquired immunodeficiency syndrome. Hum Pathol 1986; 17:926–929.

233. Wakefield AE, Pixley FJ, Banerji S, et al. Detection of Pneumocystis carinii with DNA amplification. Lancet 1990;336:451–453.

234. Wakefield AE, Guiver L, Miller RF, Hopkin JM. DNA amplification on induced sputum samples for diagnosis of Pneumocystis carinii pneumonia. Lancet 1991;337:1378–1379.

235. Lipschik GY, Gill VJ, Lundgren JD, et al. Improved diagnosis of Pneumocystis carinii infection by polymerase chain reaction on induced sputum and blood. Lancet 1992;340:203–206.

236. Saito K, Nakayamada S, Nakano K., et al. Detection of Pneumocystis carinii by DNA amplification in patients with connective tissue diseases: re-evaluation of clinical features of P. carinii pneumonia in rheumatic diseases. Rheumatology 2004;43:479–485.

237. Brancart F, Rodriguez-Villalobos H, Fonteyne PA, et al. Quantitative TaqMan PCR for detection of Pneumocystis jiroveci. J Microbiol Methods 2005;61:381–387.

238. Blumenfeld W, McCook O, Holodny M, Katzenstein DA. Correlation of morphologic diagnosis of Pneumocystis carinii with the presence of pneumocystis DNA amplified by the polymerase chain reaction. Mod Pathol 1992;5: 103–106.
239. Pifer LL, Hughes WT, Murphy MJ. Propagation of Pneumocystis carinii in vitro. Pediatr Res 1977;11:305–316.

240. Cushion MT, Walzer PD. Growth and serial passage of Pneumocystis carinii in the A549 cell line. Infect Immun 1984;44:245–251.

241. Maddison SE, Walls KW, Haverkos HW, Juranek DD. Evaluation of serologic tests for Pneumocystis carinii antibody and antigenemia in patients with acquired immunodeficiency syndrome. Diagn Microbiol Infect Dis 1984;2:69–73.

242. Walzer PD. Diagnosis of Pneumocystis carinii pneumonia. J Infect Dis 1988;157:629–632.

243. Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med 1988;109:280–287.

244. Kovacs JA, Masur H. Pneumocystis carinii pneumonia: therapy and prophylaxis. J Infect Dis 1988;158:254–259.

245. Sattler FR, Feinberg J. New developments in the treatment of Pneumocystis carinii pneumonia. Chest 1992;101:451–457.

246. NIH-UC Expert Panel. Consensus statement on the use of adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990;323:1500–1504.

247. CDC. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR 1992;41 (no. RR-4):1–11.

248. DeRoux SJ, Adsay V, Ioachim HL. Disseminated pneumocystosis without pulmonary involvement during prophylactic aerosolized pentamidine therapy in a patient with the acquired immunodeficiency syndrome. Arch Pathol Lab Med 1991;115:1137–1140.

249. Falloon J, Kovacs J, Hughes W, et al. A preliminary evaluation of 566CB0 for the treatment of pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 1991;325:1534–1538.